Taylor Cancer Research Center

Maumee, Ohio 43537

22 studies enrolling now · 26 studies all time

What they study most

ALK-Positive Lung Cancer, ALK-positive NSCLC, ALK-positive Non-small Cell Lung Cancer, Acinar Cell Carcinoma, Acute Myeloid Leukaemia (AML), Advanced Cancer, Advanced Non-small Cell Lung Cancer, HER2 Mutation, Advanced Solid Tumors, Advanced Solid Tumors Cancer, Advanced/Metastatic Solid Tumors, B-cell Malignancy, Bladder Cancer

Studies at this site

• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting now
• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) — Recruiting now
• Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Recruiting now
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — Recruiting now
• A Study of ASP3082 in Adults With Advanced Solid Tumors — Recruiting now
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — Recruiting now
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC — Recruiting now
• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations — Recruiting now
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Recruiting now
• A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies — Recruiting now
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting now
• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC — Recruiting now
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS — Recruiting now
• A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. — Recruiting now
• TEMPUS ARIES: A Biobank Registry Platform Study in Oncology — Recruiting now
• Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors — Recruiting now
• GEMINI-NSCLC: NSCLC Biomarker Study — Recruiting now
• AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma — Recruiting now
• Pan-tumor MRD Study — Recruiting now
• A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer — Running, not enrolling
• Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors — Available (expanded access)
• Umbrella Study for Analysis of Data Related to Patients With Cancer — Completed
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP — Running, not enrolling